JPH0725773A - Analgesic cream - Google Patents
Analgesic creamInfo
- Publication number
- JPH0725773A JPH0725773A JP19672393A JP19672393A JPH0725773A JP H0725773 A JPH0725773 A JP H0725773A JP 19672393 A JP19672393 A JP 19672393A JP 19672393 A JP19672393 A JP 19672393A JP H0725773 A JPH0725773 A JP H0725773A
- Authority
- JP
- Japan
- Prior art keywords
- cream
- analgesic
- pain
- potassium
- old woman
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006071 cream Substances 0.000 title claims abstract description 34
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 24
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 16
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims abstract description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 14
- 235000011056 potassium acetate Nutrition 0.000 claims abstract description 8
- 239000001103 potassium chloride Substances 0.000 claims abstract description 8
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 229940098465 tincture Drugs 0.000 claims description 7
- 235000002566 Capsicum Nutrition 0.000 claims description 6
- 239000001390 capsicum minimum Substances 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 5
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 5
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 12
- 230000036407 pain Effects 0.000 abstract description 12
- 210000003423 ankle Anatomy 0.000 abstract description 7
- 210000003127 knee Anatomy 0.000 abstract description 6
- 238000013329 compounding Methods 0.000 abstract description 3
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 208000006820 Arthralgia Diseases 0.000 description 16
- 208000024765 knee pain Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 159000000003 magnesium salts Chemical class 0.000 description 6
- 241000208293 Capsicum Species 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- -1 Polyoxyethylene Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000008311 hydrophilic ointment Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、鎮痛クリームに関す
る。特に、膝、足首、肩、腰等の痛みを解消するカリウ
ム塩及びマグネシウム塩を配合した鎮痛クリームに関す
るものである。FIELD OF THE INVENTION The present invention relates to an analgesic cream. In particular, the present invention relates to an analgesic cream containing a potassium salt and a magnesium salt for relieving pain in the knees, ankles, shoulders, lower back and the like.
【０００２】[0002]
【従来の技術】かかる関節等の鎮痛剤としては、従来か
ら種々のものが知られている。たとえば、コーチゾン等
のステロイド剤を配合したもの、インドメタシン等の非
ステロイド系消炎鎮痛剤を配合したものが用いられてい
る。しかし、これらは用い方によっては、組織、ホルモ
ンのアンバランス、眼障害等の副作用が問題とされてい
る。また、これらの薬剤は、必ずしも改善効果が十分で
あるとはいえないケースが存在する。2. Description of the Related Art Various pain relievers such as joints have been known. For example, those containing steroid agents such as cortisone and those containing non-steroidal anti-inflammatory analgesics such as indomethacin are used. However, depending on how they are used, side effects such as tissue and hormonal imbalances and eye disorders are problematic. In addition, there are cases in which these drugs do not always have sufficient improvement effects.
【０００３】一方、アルカリ性の植物成分が、鎮痛効果
に優れていることは昔から知られている。アルカリ性の
植物成分は、カリウム、マグネシウム等の人間にとって
貴重な成分が含まれているため、炎症を伴う痛みに対す
る治療に効果的であると思われる。カリウム塩は、細胞
内の主要電解質で、細胞膜電位の形成、酸塩基平衝の調
節、浸透圧の維持等に関与し、神経の興奮や各組織の細
胞内代謝に重要な役割を持っている。On the other hand, it has long been known that alkaline plant components have excellent analgesic effects. Alkaline plant components, which are valuable to humans such as potassium and magnesium, are considered to be effective in treating pain associated with inflammation. Potassium salt is a major electrolyte in the cell, is involved in the formation of cell membrane potential, regulation of acid-base equilibrium, maintenance of osmotic pressure, etc., and has an important role in nerve excitement and intracellular metabolism of each tissue. .
【０００４】[0004]
【発明が解決しようとする課題】本発明者は、前記のよ
うな問題や欠点のない鎮痛効果を要する鎮痛クリームを
得るべく研究を重ねた結果、カリウム塩及びマグネシウ
ム塩を配合したクリームが極めて優れた鎮痛作用を有す
ることを見いだし、本発明の鎮痛クリームの開発に成功
した。DISCLOSURE OF INVENTION Problems to be Solved by the Invention As a result of repeated studies to obtain an analgesic cream that requires the analgesic effect without the above problems and drawbacks, the present inventor has found that a cream containing a potassium salt and a magnesium salt is extremely excellent. It was found that they have an analgesic effect and succeeded in developing the analgesic cream of the present invention.
【０００５】[0005]
【課題を解決するための手段】即ち、本発明の鎮痛クリ
ームは、基剤に、１以上のカリウム塩及び１以上のマグ
ネシウム塩を配合した鎮痛クリームである。カリウム塩
としては、塩化カリウム、酢酸カリウム、またはアスパ
ラギン酸カリウムが好ましい。最も好ましいカリウム塩
は塩化カリウムと酢酸カリウムである。マグネシウム塩
としては、硫酸マグネシウムが好ましい。本発明におい
て最も好ましい組み合わせは、塩化カリウム及び酢酸カ
リウムと硫酸マグネシウムを配合した鎮痛クリームであ
り。該クリームは、実際の用途に応じて、クリーム、化
粧水、乳剤、湿布剤、軟膏剤、パスタ剤、ローション
剤、チンキ剤、リニメント剤、ゼリー剤、エアゾール剤
等の外用医薬品、及び浴用剤のような剤型にすることが
できる。他の配合成分は、通常用いられているどのよう
な成分でも良く、さらに、他の薬剤成分と併用しても良
い。That is, the analgesic cream of the present invention is an analgesic cream in which a base is mixed with one or more potassium salts and one or more magnesium salts. The potassium salt is preferably potassium chloride, potassium acetate, or potassium aspartate. The most preferred potassium salts are potassium chloride and potassium acetate. As the magnesium salt, magnesium sulfate is preferable. The most preferable combination in the present invention is an analgesic cream containing magnesium sulfate and potassium chloride and potassium acetate. The cream is a cream, a lotion, an emulsion, a poultice, an ointment, a pasta agent, a lotion, a tincture, a liniment, a jelly agent, an aerosol agent, or other external medicine, and a bath agent depending on the actual use. It can be made into such a dosage form. The other compounding ingredients may be any commonly used ingredients, and may be used in combination with other drug ingredients.
【０００６】クリーム基剤は、本発明の配合成分である
カリウ塩、マグネシウム塩と適合するものであればどの
ような基剤でも良い。日本薬局方の親水軟膏が便利であ
る。親水ワセリンも好ましい。本発明の鎮痛クリームに
はイオウ、トウガラシチンキまたは沈降炭酸カルシウム
を添加することが好ましいが、本発明に必須ではない。
イオウは角質の軟化作用により薬剤の患部浸透を容易に
する働きがあるので配合することが好ましい。イオウを
添加する場合は、基剤中で他の配合成分と固着するのを
防ぐため最初にクリーム基本剤に添加するのが好まし
い。トウガラシチンキは、血行を良好にするので添加す
るのが好ましい。The cream base may be any base as long as it is compatible with the compounding ingredients of the present invention such as the potassium salt and magnesium salt. Hydrophilic ointment of Japanese Pharmacopoeia is convenient. Hydrophilic petrolatum is also preferred. Although it is preferable to add sulfur, capsicum tincture, or precipitated calcium carbonate to the analgesic cream of the present invention, it is not essential to the present invention.
Sulfur has a function of facilitating the penetration of the drug into the affected area due to the softening action of keratin, and therefore it is preferably blended. When sulfur is added, it is preferably added first to the cream base in order to prevent sticking with other ingredients in the base. Capsicum tincture is preferably added because it improves blood circulation.
【０００７】[0007]
【作用】本発明の鎮痛クリームは、基剤に、カリウム
塩、マグネシウム塩を含有するため、カリウム、マグネ
シウム等の人間にとって貴重な成分を含むため、皮膚か
らの吸収を通じて血中に取り込まれ、鎮痛作用を生じる
ものと推定される。The analgesic cream of the present invention contains potassium salts and magnesium salts in its base, and therefore contains valuable ingredients for humans such as potassium and magnesium. Therefore, the analgesic cream is taken into the blood through absorption through the skin to provide analgesia. It is presumed to cause an effect.
【０００８】[0008]
【実施例】以下に本発明の実施例を示し、本発明をさら
に詳細に説明するが本発明を限定するものではない。 実施例１ 鎮痛クリームその１ 全量を１００ｇとした重量（ｇ） 白色ワセリン １１ ステアリン酸 ６ セタノール ３ モノステアリン酸グリセリル ２．５ ポリオキシエチレン ２．０ ステアリルエーテル ０．５ 流動パラフィン ２．０ プロピルパラベン ０．１ 精製水 ３６．８ トリエタノールアミン ０．５ プロピレングリコール ４．０ メチルパラベン ０．１ 塩化カリウム ６．０ トウガラシチンキ １．０ 酢酸カリウム １０．０ 硫酸マグネシウム ５．０ 沈降炭酸カルシウム ８．０ イオウ １．０ まず、容器にクリーム（日本薬局方親水軟膏）３０ｇを
入れ、イオウ１ｇを添加して、ヘラを用いてまんべんな
く混合し、次に、塩化カリウムを６ｇ、トウガラシチン
キを１ｇを添加した。クリームの状態がかなり柔らかく
なった時点で、沈降炭酸カルシウム８ｇを添加して攪は
んし固くする。その後、硫酸マグネシウムを５ｇ、酢酸
カリウム１０ｇを混ぜた。クリーム状態が良くなり、最
後に、残ったクリーム基剤５ｇを添加して鎮痛クリーム
を得た。The present invention will be described in more detail below with reference to examples of the present invention, but the present invention is not limited thereto. Example 1 Analgesic cream Part 1 Weight based on 100 g of total amount (g) White petrolatum 11 Stearic acid 6 Cetanol 3 Glyceryl monostearate 2.5 Polyoxyethylene 2.0 Stearyl ether 0.5 Liquid paraffin 2.0 Propylparaben 0 .1 Purified water 36.8 Triethanolamine 0.5 Propylene glycol 4.0 Methylparaben 0.1 Potassium chloride 6.0 Capsicum tincture 1.0 Potassium acetate 10.0 Magnesium sulfate 5.0 Precipitated calcium carbonate 8.0 Sulfur 1 0.0 First, 30 g of cream (hydrophilic ointment in the Japanese Pharmacopoeia) was added to a container, 1 g of sulfur was added and mixed thoroughly with a spatula, and then 6 g of potassium chloride and 1 g of capsicum tincture were added. When the cream has become fairly soft, 8 g of precipitated calcium carbonate is added to stir and stiffen. Then, 5 g of magnesium sulfate and 10 g of potassium acetate were mixed. The cream state improved, and finally, 5 g of the remaining cream base was added to obtain an analgesic cream.
【０００９】このクリームを４５から７２才の膝、足首
等に痛みを有する男性４名、女性１６名に塗布して、そ
の効果を検討した。塗布前の症状は次のと通りである。 番号 年齢 性別 症状 ─────────────────────────────────── １ ６８才 男 左足首痛み ２ ６２才 男 右膝痛み ３ ５６才 男 膝痛み ４ ５９才 男 膝痛み ５ ６１才 女 両膝痛み ５ ６１才 女 両膝痛み ６ ５８才 女 両膝痛み ７ ６０才 女 膝痛み ８ ４５才 女 右膝痛み ９ ６２才 女 右膝痛み １０ ７０才 女 左膝痛み １１ ５４才 女 右足首痛み １２ ７０才 女 左膝痛み １３ ５９才 女 左膝痛み １４ ６０才 女 左膝痛み １５ ６５才 女 右足首左膝痛み １６ 才 女 両膝痛み １７ ６８才 女 両膝痛み １８ ６８才 女 右膝痛み １９ ６３才 女 足のしびれ、両足のだるさ ２０ ７２才 女 両膝痛みThis cream was applied to 4 males and 16 females aged 45 to 72 years who have pains in the knees, ankles, etc., and the effect was examined. The symptoms before application are as follows. Number Age Gender Symptoms ─────────────────────────────────── 1 68 years old Left ankle pain 2 62 years old Male Right knee pain 3 56 years old Man knee pain 4 59 years old Man knee pain 5 61 years old Woman both knee pain 5 61 years old woman Both knees pain 6 58 years old Woman both knees pain 7 60 years old Woman knee pain 8 45 years old Woman right knee pain 9 62 year old woman right knee pain 10 70 year old woman left knee pain 11 54 year old woman right ankle pain 12 70 year old woman left knee pain 13 59 year old woman left knee pain 14 60 year old woman left knee pain 15 65 year old woman right ankle left knee pain 16-year-old woman with both knee pain 17 68-year-old woman with both knee pain 18 68-year-old woman with right knee pain 19 63-year-old woman with numbness in the legs and dullness of both feet 20 72-year-old woman with both knee pain
【００１０】症状別の使用効果は次の通りである。 痛み（全１９例） 良くなった １９名中１６名 少し良くなった（５０％） １９名中 ３名 変わらない １９名中 ０名 しびれ、だるさ（全１例） 良くなった １名中１名 少し良くなった（５０％） １名中０名 変わらない １名中０名The effects of use according to symptoms are as follows. Pain (19 cases in total) Improved 16 out of 19 slightly improved (50%) 3 out of 19 unchanged 3 out of 19 0 numbness and dullness (all 1 case) Improved 1 out of 1 A little better (50%) 0 out of 1 unchanged 0 out of 1
【００１１】このように、本発明による鎮痛クリーム塗
布の結果、多くの試験者において効果が認められた。次
に、１日において、何回の塗布による効果であるかを示
したのが次の表である。 ──────────────────────────────────── 良好 やや良くなった 変わらない ──────────────────────────────────── １日１回 １ ０ ０ ──────────────────────────────────── １日２回 ６ １ ０ ──────────────────────────────────── １日３回 ９ ２ ０ ───────────────────────────────────As described above, as a result of the application of the analgesic cream according to the present invention, the effect was recognized by many testers. Next, the following table shows how many times the effect is applied in one day. ──────────────────────────────────── Good slightly improved steadily ─────── ───────────────────────────── Once a day 10 0 ─────────────── ────────────────────── twice a day 6 10 ───────────────────── ─────────────── 3 times a day 9 20 ───────────────────────────── ───────
【００１２】また、効果が出始めたのは何日目からかを
示したのが下記である。 効きはじめ 塗布 １−３日目から ３ 名 ４−６日目から ８ 名 ７−１３日目から ８ 名 １４日目から以降 １ 名In addition, the following shows how many days the effects began to appear. Beginning of effect Application 1-3 days from 3 people 4-6 days from 8 people 7-13 days from 8 people 14 days from then 1 person
【００１３】以上から、本発明の鎮痛クリームは、試験
者の１００％に鎮痛効果が認められた。また、その効果
の現れ方が、塗布後２週間以内に９５％にも達した。３
日以内に効果が現れたケースも２０％の試験者に認めら
れた。さらに、１日２−３回の塗布で十分効果があり、
また、全例において、副作用は全く見られなかった。From the above, the analgesic cream of the present invention was found to have an analgesic effect in 100% of testers. In addition, the appearance of the effect reached 95% within 2 weeks after application. Three
In some cases, 20% of the testers showed the effect within the day. Furthermore, application 2-3 times a day is sufficiently effective,
No side effects were observed in any of the cases.
【００１４】 実施例２ 鎮痛クリームその２ 全量を８９．５ｇとした場合の重量（ｇ） 白色ワセリン １１．０ ステアリン酸 ６．０ セタノール ３．０ モノステアリン酸グリセリル ２．５ ポリオキシエチレン ２．０ ステアリルエーテル ０．５ 流動パラフィン ２．０ プロピルパラベン ０．１ 精製水 ３６．８ トリエタノールアミン ０．５ プロピレングリコール ４．０ メチルパラベン ０．１ 塩化カリウム ６．０ 酢酸カリウム １０．０ 硫酸マグネシウム ５．０ イオウ、トウガラシチンキ及び沈降炭酸カルシウムを添
加しない他は、実施例１と同様の操作を行い、鎮痛クリ
ームその２を得た。このクリームを実施例１と同様に痛
みを有する試験者に塗布して効果を見たところ、ほぼ９
０％の試験者に痛みの改善が見られた。また、副作用も
全く見られなかった。Example 2 Analgesic cream No. 2 Weight (g) when the total amount is 89.5 g White petrolatum 11.0 Stearic acid 6.0 Cetanol 3.0 Glyceryl monostearate 2.5 Polyoxyethylene 2.0 Stearyl ether 0.5 Liquid paraffin 2.0 Propylparaben 0.1 Purified water 36.8 Triethanolamine 0.5 Propylene glycol 4.0 Methylparaben 0.1 Potassium chloride 6.0 Potassium acetate 10.0 Magnesium sulfate 5.0 Analgesic cream 2 was obtained by performing the same operation as in Example 1 except that sulfur, capsicum tincture and precipitated calcium carbonate were not added. When this cream was applied to a tester who had pain in the same manner as in Example 1, the effect was found to be about 9
Improved pain was seen in 0% of the testers. Also, no side effects were observed.
【００１５】[0015]
【発明の効果】本発明は、以上詳述したように、主とし
て、膝、足首等の痛みに著効で、副作用も全くなく、治
療効果が認められた。As described in detail above, the present invention is mainly effective for pains in the knees, ankles, etc., and has no side effect at all, and a therapeutic effect was recognized.
Claims (2)
酸カリウムの少なくとも１以上と硫酸マグネシウムを配
合したことを特徴とする鎮痛クリーム。1. An analgesic cream comprising a cream base and at least one of potassium chloride or potassium acetate and magnesium sulfate.
酸カルシウムの少なくとも１つ以上ををさらに含む請求
項１のクリーム。2. The cream of claim 1 further comprising at least one or more of sulfur, capsicum tincture or precipitated calcium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19672393A JPH0725773A (en) | 1993-07-15 | 1993-07-15 | Analgesic cream |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19672393A JPH0725773A (en) | 1993-07-15 | 1993-07-15 | Analgesic cream |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0725773A true JPH0725773A (en) | 1995-01-27 |
Family
ID=16362530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19672393A Withdrawn JPH0725773A (en) | 1993-07-15 | 1993-07-15 | Analgesic cream |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0725773A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3693020A1 (en) * | 2019-02-08 | 2020-08-12 | Burmaster International Group GmbH | Potassium enriched topical formulations for pain relief and sleep aid |
-
1993
- 1993-07-15 JP JP19672393A patent/JPH0725773A/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3693020A1 (en) * | 2019-02-08 | 2020-08-12 | Burmaster International Group GmbH | Potassium enriched topical formulations for pain relief and sleep aid |
| CN112055583A (en) * | 2019-02-08 | 2020-12-08 | 布莱恩·伯马斯特 | Potassium-enriched topical formulation for pain relief and sleep aid |
| JP2022519400A (en) * | 2019-02-08 | 2022-03-24 | バーマスター、ブライアン | Potassium-enriched topical preparation for analgesia relief and sleep support |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dahl et al. | 12% lactate lotion for the treatment of xerosis: a double-blind clinical evaluation | |
| Lin et al. | Salicylic acid revisited. | |
| PT1079804E (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANPHOTERIC TENSILE, A POLYPROPOXYLED ALCOHOL AND A POLAR DRUG | |
| US6613800B1 (en) | Method and compositions for treating psoriasis, eczema, seborrhea and arthritis | |
| JPH05117158A (en) | External preparation composition for skin | |
| USRE36606E (en) | Synergistic pharmaceutical compositions | |
| WALDORF et al. | Vitamin A—responsive pityriasis rubra pilaris with myasthenia gravis | |
| RU2496476C1 (en) | External therapeutic agent for patients suffering atopic dermatitis | |
| JPH03227921A (en) | Remedy for keloid | |
| US20050152993A1 (en) | Composition for and method of treatment for skin ailments | |
| JPS6259219A (en) | Antitussive, expectorant, analgesic and sedative agent for external use | |
| US12303476B2 (en) | Compositions and methods of achieving pain relief | |
| JPS59216812A (en) | Hair restoring agent | |
| TW442281B (en) | Pharmaceutical compositions for treating psoriasis and other hyperkeratotic and/or scaly dermatoses | |
| JP5460766B2 (en) | Pharmaceutical composition for external use | |
| JPH0137370B2 (en) | ||
| JPS62155214A (en) | Antiinflammatory drug and method | |
| JPS6028919A (en) | Dermatic drug for external application | |
| JPS6028927A (en) | External preparation for skin | |
| RU2517520C1 (en) | External therapeutic agent for patients suffering from atopic dermatitis | |
| JP2828185B2 (en) | Bath composition | |
| JPH08165244A (en) | Skin disease treatment | |
| JPS6028926A (en) | External preparation for skin | |
| JPH08295626A (en) | Alkaline analgesic cream for joint | |
| JPS60188316A (en) | Anti-inflammatory for oral cavity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20001003 |